title: Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.
abstract: OBJECTIVE
  To observe the efficacy and safety of albumin-bound paclitaxel (ABP) monotherapy in treating recurrent advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  We retrospectively analyzed the short-term efficacy and toxicities of ABP monotherapy in treating 21 patients who had previously undergone multiple cycles of therapy for their advanced NSCLC in our hospital since 2010. The treatment-related survival was also analyzed.
  
  
  RESULTS
  Of these 21 patients, the best overall response was partial response (PR) in 6 patients (28.6%), stable disease (SD) in 10 patients (47.6%), and progressive disease (PD) in 5 patients (23.8%). The overall response rate (ORR) was 28.6% and the disease control rate (DCR) (PR + SD) was 76.2%. The median progression-free survival (PFS) was 4.0 months (95% CI, 5.0-7.0 months). The main grade 3/4 toxicities included neutropenia (11.1%), peripheral nerve toxicity (5.6%), muscle and joint aches (5.6%), and fatigue (5.6%).
  
  
  CONCLUSIONS
  The ABP monotherapy can achieve good objective response in advanced NSCLC patients who have previously received multiple cycles of treatment and be well tolerated.
authors.affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
authors.forename: Pu-Yuan
authors.initials: PY
authors.lastname: Xing
authors.forename: Jun-Ling
authors.initials: JL
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Xue-Zhi
authors.initials: XZ
authors.lastname: Hao
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.forename: Yuan-Kai
authors.initials: YK
authors.lastname: Shi
authors.forename: Xiang-Ru
authors.initials: XR
authors.lastname: Zhang
keywords: Albumin-bound paclitaxel; advanced non-small cell lung cancer; chemotherapy; paclitaxel